The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m ...

Eye colour: gold, copper, green, hazel, blue, or two different colored eyes ...

Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular ...

The press release highlights that there are currently no available disease-modifying treatments for Fuchs endothelial corneal dystrophy, emphasizing the seriousness and lack of options for ...